- Home
- NCA vs FHTX Comparison
NCA vs FHTX Comparison
Compare NCA & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCA
- FHTX
- Stock Information
- Founded
- NCA 1987
- FHTX 2015
- Country
- NCA United States
- FHTX United States
- Employees
- NCA N/A
- FHTX N/A
- Industry
- NCA Investment Managers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NCA Finance
- FHTX Health Care
- Exchange
- NCA Nasdaq
- FHTX Nasdaq
- Market Cap
- NCA 280.8M
- FHTX 278.1M
- IPO Year
- NCA N/A
- FHTX 2020
- Fundamental
- Price
- NCA $8.72
- FHTX $5.19
- Analyst Decision
- NCA
- FHTX Strong Buy
- Analyst Count
- NCA 0
- FHTX 6
- Target Price
- NCA N/A
- FHTX $11.33
- AVG Volume (30 Days)
- NCA 59.6K
- FHTX 85.6K
- Earning Date
- NCA 01-01-0001
- FHTX 11-03-2025
- Dividend Yield
- NCA 3.92%
- FHTX N/A
- EPS Growth
- NCA N/A
- FHTX N/A
- EPS
- NCA N/A
- FHTX N/A
- Revenue
- NCA N/A
- FHTX $24,173,000.00
- Revenue This Year
- NCA N/A
- FHTX $43.75
- Revenue Next Year
- NCA N/A
- FHTX $1.27
- P/E Ratio
- NCA N/A
- FHTX N/A
- Revenue Growth
- NCA N/A
- FHTX N/A
- 52 Week Low
- NCA $7.77
- FHTX $2.95
- 52 Week High
- NCA $9.12
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NCA 67.40
- FHTX 47.97
- Support Level
- NCA $8.51
- FHTX $5.14
- Resistance Level
- NCA $8.54
- FHTX $5.85
- Average True Range (ATR)
- NCA 0.06
- FHTX 0.35
- MACD
- NCA 0.03
- FHTX -0.00
- Stochastic Oscillator
- NCA 91.38
- FHTX 30.53
About NCA Nuveen California Municipal Value Fund
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. Its primary objective is to provide current income exempt from regular federal and California income taxes. The fund's secondary objective is to enhance portfolio value relative to the California municipal bond market by investing in tax-exempt California municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.